Clinical trials in malignant glioma have demonstrated excellent safety of recombinant adenovirus type 5 (Ad5) but lack of convincing efficacy. The overall low expression levels of the Coxsackie and Adenovirus receptor and the presence of high anti-Ad5-neutralizing antibody (NAb) titers in the human population are considered detrimental for consistency of clinical results. To identify an adenoviral vector better suited to infect primary glioma cells, we tested a library of fiber-chimeric Ad5-based adenoviral vectors on 12 fresh human glioma cell suspensions. Significantly improved marker gene expression was obtained with several Ad5-chimeric vectors, predominantly vectors carrying fiber molecules derived from B-group viruses (Ad11, Ad16, Ad35 and Ad50). We next tested Ad35 sero prevalence in sera derived from 90 Dutch cancer patients including 30 glioma patients and investigated the transduction efficiency of this vector in glioma cell suspensions. Our results demonstrate that the sero prevalence and the titers of NAb against Ad35 are significantly lower than against Ad5. Also, recombinant Ad35 has significantly increased ability to transfer a gene to primary glioma cells compared to Ad5. We thus conclude that Ad35 represents an interesting candidate vector for gene therapy of malignant glioma.
Introduction
The prognosis of malignant gliomas is dismal with an overall median survival of less than 1 year and few if any long-term survivors. 1 After initial treatment, the tumors always recur and the residual glioma cells cannot be radically excised and are resistant to radiotherapy and most chemotherapeutic agents. However, these tumor cells may be eradicated by administration of viral vectors carrying suicide genes such as thymidine kinase (TK) or cytosine deaminase (CD). 2, 3 Adenoviral vectors are among the most promising gene delivery vehicles currently available because: (1) intratumoral administration of adenovirus type 5 (Ad5)-based vectors in malignant glioma patients has demonstrated excellent safety; [4] [5] [6] [7] ( 2) high titer batches of Ad5 can be produced at large scale; (3) large segments of foreign DNA can be incorporated into Ad5 and (4) Ad5 does not integrate into the host genome. In a recently published randomized controlled study, Ad5-TK increased the median survival time from 38 to 62 weeks in malignant glioma patients. 4 However, the antitumor efficacy observed thus far remains limited and requires further improvement to become clinically relevant. [4] [5] [6] 8 At least two parameters have been identified that may contribute to the limited efficacy of Ad5-based vectors in malignant glioma trials. The first hurdle is the poor infection of primary glioma cells by Ad5, which is most likely caused by the low expression levels of the high affinity Coxsackie and Adenovirus receptor (CAR) on these cells. The second parameter is the high sero prevalence and antibody titers against Ad5 in the human population 9 that may significantly hamper gene transfer, at least in experimental animals. 10, 11 Various strategies have been employed to achieve a CAR-independent infection capacity for Ad vectors. These include the incorporation of heterologeous-binding proteins at the fiber carboxy terminus or the fiber-knob HI-loop. 12, 13 Another approach is the genetic replacement of Ad5 fiber with its structural counterpart from another human or nonhuman serotype. [14] [15] [16] [17] Resultant vectors have shown CAR-independent tropism owing to the natural diversity in receptor recognition and identified chimeric vectors with superior infectivity to Ad5 in several clinically relevant cell lines. [14] [15] [16] [17] In pursuit of a better adenoviral vector to treat malignant glioma, we screened an Ad5-based fiber-chimeric vector library (n ¼ 16) to identify chimeric vectors with an increased ability to transfer nucleic acids to primary glioma cells. We observed that Ad5 vectors carrying fibers derived from B-group adenoviruses (Ad11, Ad16, Ad35 and Ad50) transferred marker genes more efficiently than Ad5 to primary glioma cells derived from 12 different patients.
The highly prevalent immunity against Ad5 is, however, not circumvented by Ad5-based fiber-chimeric vectors. 18 Recent studies have reported that the sero prevalence of human Ad35 is significantly lower than Ad5 in healthy blood donors. 9 However, B-group adenoviruses, including Ad35, have been isolated relatively frequently from immunocompromised patients. 19 Because the immune system is variably suppressed in cancer, we studied the sero prevalence in 90 Dutch cancer patients including 30 patients with a malignant glioma. Our results demonstrated that the sero prevalence and neutralizing antibody (NAb) titers against Ad35 in cancer patients were low compared to Ad5. Finally, we generated a recombinant Ad35 vector and showed that this virus infected primary glioma cells significantly better than Ad5. Based on the low sero prevalence of Ad35 and the significantly improved infection efficiency as compared to Ad5, we conclude that Ad35-based vectors represent a promising new gene transfer vehicle for the treatment of malignant gliomas.
Materials and methods

Generation of fiber-chimeric viruses
All known human wild-type adenoviruses (types 1-51) were propagated on PER.C6 cells, 20 and viral DNA was isolated as described previously. 21 Fiber amplification and generation of fiber-chimeric viruses have been described. 16, 22 In short, fiber genes were polymerase chain reaction (PCR) amplified with distinct sets of 'subgroupspecific' oligonucleotides. The two amplified products from each fiber were sequenced and confirmed as genuine adenovirus fiber molecules by phylogenetic analysis at the DNA and amino-acid level. 16 Fiber sequences were cloned in an NdeI-and NsiI-digested pBr/Ad.BamRDFIB plasmid, thus generating a library of plasmids coded pBr/ Ad.BamRDFIBXX (where XX represents the serotype from which the fiber was amplified). Plasmid pBr/ Ad.BamRDFIB contains the Ad5 viral genome sequence from the BamHI site (nucleotide [nt] 21562) until the 3 0 end of the viral genome. The Ad5 fiber sequence (nt 31042-32787) was deleted by PCR, while simultaneously introducing unique restriction sites (NdeI and NsiI) to allow for the insertion of fiber molecules derived from other serotypes. Virus was then produced on four T175 triple-layer tissue culture flasks and purified with a twostep cesium chloride purification protocol. 15 After purification, virus was aliquoted and stored at À801C. The virus titer expressed in virus particles (VP) per milliliter was determined by high-pressure liquid chromatography. 23 Plaque purifications and end point titrations were performed as described previously. 20 A total of 16 recombinant Ad5-based chimeric viruses were produced with the luciferase marker gene driven by a modified cytomegalovirus promoter (Table 1 , Clip. Luc). 24 A limited number of recombinant Ad5-based chimeric virus was produced that contained the enhanced green fluorescent protein marker gene (Fibers 5, 16 and 35 ). An E1-lacking Ad35-based vector encoding the luciferase gene was constructed as described elsewhere. 9 Preparation and propagation of single-cell suspensions from glial tumors Brain tumor tissue was processed immediately after surgery or was stored in a 50 ml tube containing Rosewell Park Memorial Institute medium (RPMI) 1640 (Invitrogen, Breda, The Netherlands) at 41C until further handling. Primary tumor cell cultures were prepared by cutting the tissue into small pieces and 1-3 1-h digestion steps in hepatocyte liver digest medium (Invitrogen) at 371C. After every digestion step, the suspension was pipetted up and down using a 5 or 10 ml pipet to remove loose cells from the tissue. The suspension was then placed at 371C again to let the debris sink down and the single cells in the suspension were transferred to a new Immunohistochemical characterization of cells cultured from primary gliomas Cytospins of the primary glioma cell cultures were incubated for 30 min with monoclonal anti-S100 (Dako, Glostrup, Denmark) diluted 1:300 or polyclonal anti-glial fibrillary acidic protein (GFAP) (Dako) diluted 1:100 in PBS/bovine serum albumin (BSA) 1%. After washing in PBS, the samples were incubated with a secondary antibody for 30 min at room temperature (rat antimouse-biotin (Dako) or swine anti-rabbit-biotin (Dako), diluted 1:200 in PBS/BSA 1%). After washing in PBS, the samples were incubated with StreptABComplex/AP (Dako) for 30 min and flushed with PBS and Tris/HCl, pH 8.0. The cytospins were incubated for 30 min at room temperature in the dark with the chromate (Naphtol AS-MX (Sigma-Aldrich), New Fuchsine (Sigma-Aldrich), NaNO 2 , Levamisol (Across Organic, Geel, Belgium) in Tris/HCl, pH 8), flushed with water and counterstained with hematoxylin (Klinipath, Duiven, The Netherlands). Sections were mounted with Imsolmount (Klinipath) and dried at 421C. Negative control samples were treated the same with the exception that the primary antibody was replaced by the diluent. The cytospins were examined under the microscope and cells were scored as positive or negative.
CAR, integrin and CD46 expression on primary glioma tumor cells Tumor cells were trypsinized and resuspended in 10 ml medium. After centrifugation for 5 min at 450 Â g at 41C, the medium was removed and the cells were taken up in 5 ml of PBS/BSA (0.5% BSA in PBS). Cells were counted and 10 5 cells were transferred to a fluorescence-activated cell sorting (FACS) tube. After centrifugation and discarding the supernatant, 100 ml of PBA was added. Tumor cells were then stained on ice with mouse monoclonal antibodies directed against CAR, against integrins (a v b 3 or a v b 5 ) or against CD46 for 30 min in PBA. Anti-CAR was used in a dilution of 1:100 (kind gift from JM Bergelson, Dana-Farber Cancer Institute, Boston, MA), anti-a v b 3 (Chemicon International, Temecula, CA) 1:100, anti-a v b 5 (Chemicon) 1:100 and anti-CD46 1:50 (Biotrend, Cologne, Germany). After washing, cells were incubated for 25 min at 41C with phycoerythrinconjugated rat anti-mouse immunoglobulin (IgG (5 mg/ sample, Becton Dickinson) or fluorescein isothiocyanateconjugated goat-anti mouse IgG (BD Pharmingen, San Diego, CA). After centrifugation and removal of supernatant, 100 ml of PBA was added and the samples were analyzed on a FACS-Calibur (Becton Dickinson).
Infection of primary glioma tumor cells with Ad5, Ad5.FibXX and Ad35 Cells were trypsinized and plated out into 96-well plates at 10 4 cells/well in 100 ml medium. A549 cells were used as control cell line. After 24 h, viruses were added in triplicate at concentrations of 1000 and 5000 VP per cell (10 ml of 1Â 10 9 and 5 Â 0 9 VP/ml). Two hours after starting the incubation, the medium was removed, and fresh medium was added. After 48 h of incubation at 371C the medium was removed, the cells were washed with PBS and 100 ml of Reporter Lysis Buffer (Promega Benelux BV, Leiden, The Netherlands) was added. The plates were stored at À801C until analysis. To determine luciferase activity, the plates were thawed and 20 ml of cell lysate was transferred into a white 96-well flat bottom plate. After addition of 100 ml of reagent (Promega Benelux BV), the relative light units were measured in an Ascent plate reader (Thermo Labsystems, Vantaa, Finland).
Quantitation of adenovirus-NAbs
To determine the titer of Ad-NAbs in patients' sera, we used the recently validated luciferase-based Ad neutralization assay. 25 Sera were collected from 90 patients with active cancer, 30 of whom had a malignant glioma. Sera were heat inactivated at 561C for 60 min before a serial doubling dilution was performed in a 96-well culture plate. Sera were diluted in Dulbecco's modified Eagle's medium eventually resulting in dilutions ranging from 1/16 to 1/32 768 in a volume of 200 ml. No serum was added to the controls, which resulted in maximum luciferase activity. This value was used to calculate the 90% neutralization value. Patients with X90% neutralization at a titer of X32 were considered positive for NAbs.
Quantitation of Ad genomes by real-time PCR
Forty-eight hours after infection with Ad5.Luc and Ad35.Luc (multiplicity of infection (MOI) 1000), the adenoviral copy number per cell was determined with a multiplex real-time PCR reaction. 16 Total DNA was extracted by using a DNeasy Tissue Kit (Qiagen, Valencia, CA). To amplify the adenoviral DNA, specific primers Ad5Clip-F (5 0 -CGACGGATG TGGCAAAAGT-3 0 ) and Ad5Clip-R (5 0 -CCTAAAACCGCGCGAAAA-3 0 ) were used. Amplification is detected by a fluorogenic probe (Ad5Clip-Pr; 5 0 -VIC-CACCGGCGCACACCAAAAACG- 
Statistical analysis
's exact test and Mann-Whitney test, respectively. Following infection of five selected primary glioma cells (# 1, 2, 4, 9 and 11) with Ad5.Luc or Ad35.Luc, Ad genome copy number and luciferase expression were compared using t-test. Po0.05 was considered statistically significant.
Results
Characterization of primary human glioma cells
Single-cell suspensions were obtained from 12 primary human gliomas. Of the 12 gliomas, two were diagnosed (WHO 26 ) as Grade I, four as Grade II, two as grade III and four as Grade IV (Table 2 ). All primary glioma cells expressed the glia-specific intermediate filament GFAP demonstrating origin and purity of cell populations. As Ad5 binds to the CAR receptor and subsequently enters the cell via a v b 3 and a v b 5 integrins, we analyzed the primary tumor cell suspensions for expression of these proteins by FACS analysis. In 11 out of the 12 glioma cell suspensions tested, we found very low CAR expression (o5% positive cells). Also, a v b 3 integrin expression proved low, whereas expression levels of a v b 5 were readily detectable (410% of cells) on 10 of 11 glioma cell suspensions ( Table 2) . One cell suspension, clearly of glioma origin (#11), displayed high CAR expression (430% positive cells) indicating the high variability between cell preparations obtained from different tumors.
Infection of primary glioma cells with the Ad5-based fiber chimeric vector library
Following infection of the primary glioma cells suspensions with the Ad5-based fiber-chimeric vector library (Table 1) , we compared the mean luciferase expression of Ad5.FibXX with Ad5 in all 12 tumors. Results demonstrated a statistically significant difference in luciferase activity (Figure 1a ) between Ad5 and the Ad5-chimeric vectors carrying fiber molecules derived from other serotypes (MOI 1000, P ¼ 0.0001; MOI 5000, Po0.0001). Post-analysis demonstrated that Ad5-chimeric vectors carrying fiber molecules from subgroup B serotypes 11, 16, 35 and 50 and the short fiber of the F-group serotype 40 performed significantly better than Ad5 following infection with MOI 1000 and MOI 5000. For each vector, considerable differences in luciferase expression levels were observed between tumors as reflected by the error bars in Figure 1a . We next analyzed, for each tumor separately, which of the Ad5.FibXX chimeras gave a significantly higher luciferase expression level than Ad5. From these data (Figure 1b) , we conclude that in almost In Figure 2 , the transduction efficiency of these four Bgroup chimeric vectors is presented and shows that the mean luciferase expression relative to Ad5 is similar for each of these four vectors in all primary glioma cultures tested. A more than 10-fold increase in luciferase expression relative to Ad5 was obtained with all four Bgroup chimeric vectors in five of 12 primary tumor cell cultures. This similarity may indicate that Fib11, 16, 35 and 50 have similar CD46 receptor affinity or CD46 isoform recognition. Figure 3 demonstrates that the BC-1 isoform of the CD46 receptor is readily expressed on the primary glioma cell suspensions, although at variable levels.
Sero prevalence of Ad5 and Ad35 in Dutch cancer patients
The finding that B-group fiber-chimeric Ad5 vectors infect primary glioma cells better than Ad5 raised the possibility of using a vector backbone completely derived from a B-group serotype. Recent reports indicate that the sero prevalence of Ad35 is low in blood derived from healthy donors. 9 To further explore the potential of an Ad35-based vector, we compared the sero prevalence of Ad5 and Ad35 in a panel of sera derived from Dutch cancer patients. Ninety sera from cancer patients were collected, including 30 sera from patients suffering from malignant glioma. Screening of the sera (Figure 4a and b) demonstrates that Ad5 has high sero prevalence (66%) within this patient group which is significantly higher (Po0.0001) than the sero prevalence of Ad35 (31%). Also, NAb titers proved significantly higher for Ad5 as compared to Ad35 (Po0.0001). In addition, the prevalence of NAbs against Ad35 in patients suffering from malignant glioma was significantly (Po0.02) lower (17%) than in the other cancer patients (44%). These results demonstrate that the overall sero prevalence of Ad35 is low. Moreover, Ad35 seems as prevalent in sera derived from cancer patients as in sera derived from healthy blood donors. 9 Recombinant Ad35 vector transduction of primary glioma cells The increased luciferase marker gene expression levels in primary glioma cells obtained with the B-group fiberchimeric Ad5 vectors stems from improved binding of the vector to the cells because the only difference between Ad5 and Ad5.Fib35 is the fiber molecule. However, when switching from Ad5.Fib35 to Ad35, the improved transduction efficiency owing to increased binding might be obscured because of differences in intracellular trafficking between adenovirus serotypes. 9 To investigate whether recombinant Ad35 retains its superior infection and increased marker gene expression levels as compared to Ad5, we infected primary glioma cells and determined the luciferase activity as well as the number of vector genome copies per cell using quantitative PCR. Figure 5a demonstrates that the luciferase marker gene expression obtained with recombinant Ad35 is significantly higher than with Ad5 (Po0.05), as observed with Ad5.Fib35. Figure 5b shows that the increased marker gene expression results from better delivery of vector genomes into glioma cancer cells by Ad35 than by Ad5 (Po0.01).
Discussion
We tested a panel of 12 different primary human glioma cell preparations for the presence and expression level of several molecules associated with attachment and entry of 
Ad5. Although each cell preparation clearly expressed glioma-specific markers, significant differences were found between tumor isolates in CAR and integrin expression. In vitro culture artifacts are an unlikely explanation for these differences, because the tumor cell preparations were screened early after tumor isolation. These data confirm an earlier report by Fuxe et al. 27 who described variable CAR expression in 34 gliomas of various grade and demonstrated patient-to-patient variation that at present is not well understood. Although the exact function of the Ad5 high-affinity receptor CAR is not known, it is thought to be associated with adhesion and tight junction formation between cells. Furthermore, CAR expression may have a tumor suppressing effect [28] [29] [30] and correlates inversely with the aggressiveness of a tumor, explaining the low expression levels of CAR in malignant gliomas and primary glioma cells. 27, 30 In an attempt to identify a vector that uses attachment molecules other than CAR, we tested a library of 16 different Ad5-based fiber-chimeric adenoviral vectors 16 and identified five that gave significantly higher luciferase expression than Ad5 in 11 out of the 12 primary glioma cultures tested. The most efficient fiber-chimeric vectors contained a fiber molecule derived from the B-group adenoviruses Ad5.Fib11, Ad5.Fib16, Ad5.Fib35 and Ad5.Fib50, and the F-group Ad5.Fib40S. The receptor utilized by Ad40S serotype is currently unknown. The Bgroup adenoviruses were recently found to use CD46 as a high-affinity cellular attachment molecule. 31, 32 Skog et al. 33 studied the infection of seven low-passage glioma cell lines by six wild-type adenovirus serotypes, including Ad5. As determined by hexon expression, the B-group viruses Ad16 and Ad21 infected the glioma cells most efficiently, confirming the improved binding and entrance by B-group viruses as compared to CAR-binding Ad5.
The CD46 molecule is ubiquitously expressed in primates and functions to protect 'self'-cells against complement lysis by binding and inactivating C3b and C4b. 34 The expression level of the BC-1 isoform of CD46 was significantly higher than the CAR expression level on primary glioma cells, although both attachment molecules were expressed at highly variable levels. The expression of Ad35-based vectors for glioma gene therapy E Brouwer et al the BC1-isoform (one of four known isoforms of CD46) did not closely correlate with marker gene expression levels obtained after infection with the B-group fiberchimeric vectors. This may indicate that other isoforms of CD46 are perhaps expressed by these cells and may contribute to binding and internalization of the B-group fiber-chimeric vectors. As CD46 expression is very low on neurons 35 and because B-group chimeric vectors infect glioma cells more efficiently than Ad5, a recombinant vector that uses CD46 as attachment molecule might have a more favorable targeting ratio in the brain than Ad5.
In animal models, the efficiency of adenoviral gene transfer by intratumoral injection is seriously hampered by the presence of NAbs in serum. 10, 11 Although the normal brain is relatively protected from circulating IgG's, the disruption of the blood-brain barrier in malignant gliomas results in the accumulation of IgG and other large molecules in the interstitial space. 36 Therefore, circumventing the highly prevalent anti-Ad5-neutralizing activity would be important to improve adenoviral gene transfer in malignant gliomas. The recent reports of the low prevalence and serum titers of antiAd35-neutralizing activity world wide further directed attention to Ad5.Fib35. However, vaccine studies in mice demonstrated that induced anti-Ad5-neutralizing activity significantly diminished the potency of an Ad5.Fib35 vector carrying a measles antigen as compared to naı¨ve animals. This study concluded that pre-existing immunity against Ad5 is not circumvented by Ad5.Fib35. 18 On the other hand, the induced anti-Ad5-neutralizing activity could not diminish the efficiency of an Ad35-based Simian immunodeficiency virus-gag vaccine in mice. 37 Thus, recombinant Ad35 is not affected by the high Ad5 sero prevalence and, in combination with improved transduction of primary glioma cells, may represent a better vector than Ad5.
Because B-group viruses, including Ad35, are frequently isolated from immune compromised patients, 19 the sero prevalence of Ad35 might be higher in such patient groups, including patients suffering from cancer, than in the general population. Therefore, we tested sera from 90 cancer patients. In cancer patients, the Ad35 sero prevalence was significantly lower than the sero prevalence of Ad5, as in the general population. In addition, Ad35 NAb titers were generally low if present. These results are supported by recent data demonstrating that in patients progressing towards AIDS and thus becoming Figure 4 Ad-NAbs. Using a validated luciferase-based Ad neutralization assay, sera from 90 cancer patients were tested for NAbs against Ad5 and Ad35. The prevalence and titer of NAb against Ad35 is significantly lower than against Ad5 in this population (a). In addition, the prevalence of NAb against Ad35 was significantly lower in patients with primary brain tumors (n ¼ 30) than in the other cancer patients (n ¼ 60) (b). Bold bars indicate median titers. Ad35-based vectors for glioma gene therapy E Brouwer et al more immune compromised, Ad35 sero prevalence was low as compared to Ad5 whereas the number of Ad35 positive individuals did not increase with progressive immune suppression. 38 Finally, we compared the transduction efficiency of recombinant Ad35 and Ad5 on primary glioma cells. Human adenoviruses, including B-group viruses, differ substantially in intracellular trafficking, nuclear transfer efficiency and subsequent transcription and translation of the gene of interest. [39] [40] [41] We therefore examined both the Ad genome copy number per cell and the luciferase expression levels after infection of the primary glioma cells with Ad35 and Ad5. Following infection with Ad35, the Ad genome copy number per cell proved significantly higher than after Ad5 infection. Also, the luciferase marker gene expression was significantly higher following infection with Ad35 than with Ad5. These findings indicate that the high expression levels obtained by B-group fiber chimeras are due to improved entry.
In summary, we have shown that primary glioma cells express low levels of the Ad5 receptor CAR, seriously reducing the susceptibility of these cells to Ad5-mediated gene transfer. Also, we identified Ad5-based vectors carrying fiber molecules, predominantly of B-group origin, that improved gene transfer as indicated by significantly increased luciferase marker gene activity. We further demonstrate that Ad35 has low sero prevalence among Dutch cancer patients and in particular in glioma patients, circumventing the high Ad5 sero prevalence. Finally, we demonstrate that recombinant Ad35 is well suited to infect primary glioma cells. Taken together, we conclude that recombinant Ad35 represents an interesting new candidate vector for gene therapy of malignant glioma.
